(S)-N-cyclohexyl-2-((3-fluorophenyl)amino)-2-phenylacetamide | 1355328-39-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-cyclohexyl-2-((3-fluorophenyl)amino)-2-phenylacetamide
• 英文别名: (S)-N-Cyclohexyl-2-(3-fluoro-phenylamino)-2-phenyl-acetamide；(2S)-N-cyclohexyl-2-(3-fluoroanilino)-2-phenylacetamide
• CAS: 1355328-39-0
• 化学式: C₂₀H₂₃FN₂O
• 分子量: 326.414
• InChiKey: UHAMXNHIVQVPKE-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-噻吩乙酰氯 、 (S)-N-cyclohexyl-2-((3-fluorophenyl)amino)-2-phenylacetamide 在 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 以21%的产率得到(2S)-N-cyclohexyl-2-(3-fluoro-N-(2-thiophen-2-ylacetyl)anilino)-2-phenylacetamide
  参考文献：
  名称：

  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

  摘要：

  Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good potency in the U87 R132H cell based assay and similar to 90% tumor 2-HG inhibition in the corresponding mouse xenograft model following BID dosing. The magnitude and duration of tumor 2-HG inhibition correlates with free plasma concentration.

  DOI：

  10.1021/ml300225h
• 作为产物：
  描述：

  D-扁桃酸 在 吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 (S)-N-cyclohexyl-2-((3-fluorophenyl)amino)-2-phenylacetamide
  参考文献：
  名称：

  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

  摘要：

  Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good potency in the U87 R132H cell based assay and similar to 90% tumor 2-HG inhibition in the corresponding mouse xenograft model following BID dosing. The magnitude and duration of tumor 2-HG inhibition correlates with free plasma concentration.

  DOI：

  10.1021/ml300225h

文献信息

• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Popovici-Muller Janeta

  公开号：US20130184222A1

  公开（公告）日：2013-07-18

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.

  提供了一种治疗癌症的方法，其特征在于存在IDH1基因突变等位基因，包括向需要此类治疗的受试者施用此处所述的化合物。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP2593425A1

  公开（公告）日：2013-05-22
• [EN] THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE<br/>[FR] COMPOSITIONS THÉRAPEUTIQUEMENT ACTIVES ET MÉTHODE D'UTILISATION CORRESPONDANTE
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2012009678A1

  公开（公告）日：2012-01-19

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
• Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG <i>in Vivo</i>
  作者：Janeta Popovici-Muller、Jeffrey O. Saunders、Francesco G. Salituro、Jeremy M. Travins、Shunqi Yan、Fang Zhao、Stefan Gross、Lenny Dang、Katharine E. Yen、Hua Yang、Kimberly S. Straley、Shengfang Jin、Kaiko Kunii、Valeria R. Fantin、Shunan Zhang、Qiongqun Pan、Derek Shi、Scott A. Biller、Shinsan M. Su

  DOI：10.1021/ml300225h

  日期：2012.10.11

  Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good potency in the U87 R132H cell based assay and similar to 90% tumor 2-HG inhibition in the corresponding mouse xenograft model following BID dosing. The magnitude and duration of tumor 2-HG inhibition correlates with free plasma concentration.